Company”) would like to announce the operating results for the 2Q 2018 and 1H 2018, which has been reviewed by an auditor as follows: For the 2Q 2018, the Company announces a consolidated net loss of

3344 Fax. 66 2 654 3323 No. PACE IR2018/015 Date: 14 August 2018 Subject: Explanation of the Operating Results for the second quarter of the year 2018 ended 30 June 2018 changing over 20% To: The

Company Limited and its subsidiaries (“the Company”) would like to announce the operating results for the three-month and nine-month periods ended September 30, 2018, which has been reviewed by an auditor

/2561 November 12, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q3/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited

Microsoft Word - Oishi MDA - Year End 2018_EN_v2_Sud.docx Ref. SorNor. 040/2018 November 20, 2018 Subject: Clarification of Operating Results and Financial Status for the year 2018, ended September

No. IFS 057/2562 7 October 2019 Subject Management Discussion and Analysis of the 2nd Quarter 2019 Operating Results Dear Governors and President Market for Alternative Investment (mai) Infraset

วันที่ 14 สิงหาคม 2550 DEMCO Public Company Limited No. Demco AC004/2019 November 13, 2019 Subject : The company’s operating result for the 3rd quarter of year 2019 To : The president, The Stock

. per share 3.4. Paid-up capital of Preferred share 20,000,000 Shares 10 INR. per share 4. Summary of operating results for the year ended 2018 and period ended 6M/2019 of the joint venture companies 6

. Paid-up capital of Preferred share 20,000,000 Shares 10 Indian Rupees per share 4. Summary of operating results for the year ended 2018 and period ended 6M/2019 of the joint venture companies 6 Months

  TorThor. 35/2556 Standard Conduct of Business, Management Arrangement, Operating Systems, and Providing Services to Clients of Securities Companies and Derivatives Intermediaries (Codefied)   06/09/2013 01